Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Not Applicable

Active, not recruiting

• Conditions: Recurrent, Refractory, or High Risk Leukemias; Matched Targeted Therapy
• Interventions: Genetic: Leukemia Profiling

• Registration Number: NCT02670525
• Lead Sponsor: Dana-Farber Cancer Institute

Brief Summary

This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults.

This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of physicians, scientists and pharmacists. This may result in a recommendation for a specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the participant's primary oncologist.

Detailed Description

Our tissues and organs are made up of cells. Cancer occurs when the molecules that normally control cell growth are damaged. The damage results in unchecked cell growth which causes a tumor, a collection of cancer cells. The damage is referred to as an alteration. There are different types of cancer-causing alterations. Genes are the part of cells that contain the instructions which tell our cells how to make the right proteins to grow and work. Genes are composed of Deoxyribonucleic Acid (DNA) letters that spell out these instructions.

By participating in this study, the participant's leukemia cells will be tested for cancer causing alterations. This testing is called leukemia profiling. The leukemia profiling will be performed using bone marrow or blood that has already been obtained during a clinical test. Alternately, the profiling may be done on leukemia cells that are planned to be obtained as part of routine clinical care.

This study will determine whether it is possible to use profiling results to determine a matched targeted therapy for patients with leukemia. It will describe the range of mutations found in patients with leukemia with this type of profiling, and describe the clinical outcomes of patients who receive a matched targeted therapy.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-01-28
• Study First Submitted QC: 2016-01-29
• Study First Posted: 2016-02-01
• Study Start: 2016-08-17
• Primary Completion: 2022-05-16
• Results First Submitted: 2023-05-15
• Results First Submitted QC: 2023-06-29
• Results First Posted: 2023-07-18
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-04
• Last Update Posted: 2024-11-05
• Study Completion: 2027-05

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 338

Inclusion Criteria

• Birth to ≤ 30 years at study entry
• Diagnosis: Patients will be enrolled in one of the two cohorts based on diagnosis:

Cohort 1: Relapsed/refractory leukemia

• Acute lymphoblastic leukemia (ALL), first or greater relapse
• Acute myeloid leukemia (AML), first or greater relapse
• Leukemia refractory to induction chemotherapy
• Other recurrent leukemia
• Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy

Cohort 2: New diagnosis

• Acute myeloid leukemia (AML), new diagnosis
• New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (<40 chromosomes) ALL
• Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage
• Secondary leukemia
• Myelodysplastic syndrome (MDS) not eligible for stem cell transplant

Pathologic Criteria

• Histologic confirmation of leukemia at the time of diagnosis or recurrence

Specimen Samples

• Sufficient leukemia specimen available for profiling from diagnosis or recurrence OR bone marrow aspirate/blood draw/pheresis/other fresh sample of patient leukemia cells planned for clinical care anticipated to allow collection of minimum specimen for testing.

Read More

Exclusion Criteria

• Insufficient leukemia specimen available for profiling from diagnosis or recurrence; or bone marrow evaluation/blood draw/other leukemia cell sample NOT planned to be obtained for clinical care; or peripheral blast percentage <20% AND clinical blood draw not planned.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
New Diagnosis	Leukemia Profiling	Cohort 2: New Diagnosis * Acute myeloid leukemia (AML), new diagnosis (excluding acute promyelocytic leukemia (APL)) * New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (\<40 chromosomes) ALL * Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage * Secondary leukemia * Myelodysplastic syndrome (MDS) not eligible for stem cell transplant After the screening procedures confirms eligibility: * Leukemia Profiling will be performed * Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.
Relapsed/Refractory Leukemia	Leukemia Profiling	Cohort 1: Relapsed/Refractory Leukemia * Acute lymphoblastic leukemia (ALL), first or greater relapse * Acute myeloid leukemia (AML), first or greater relapse * Leukemia refractory to induction chemotherapy * Other recurrent leukemia * Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy After the screening procedures confirms patient eligibility: * Leukemia Profiling will be performed * Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.

Primary Outcome Measures

Name	Time	Method
Rate of Patients With Actionable Alterations	Actionable alteration was identified based on a combination of fluorescence in situ hybridization (FISH)/cytogenetics and sequencing. Average time to full results was 2 weeks.	An actionable alteration was defined as a cancer-associated genomic event for which there was a targeted drug available. Actionable genetic alterations were identified by a combination of standard-of-care cytogenetics/fluorescence in situ hybridization (FISH) and sequencing performed as part of the study. This study is considered feasible if at least 13% of participants analyzed have profile data and identifiable actionable alterations. A 90% exact binomial confidence interval is presented for the rate of patients with actionable alterations to compare the observed rate against 13%.

Secondary Outcome Measures

Name	Time	Method
Rate of Somatic Genomic Alterations	2 Years	This Secondary Outcome will be addressed by describing the somatic genomic alterations in Cohort 1 (Relapsed/Refractory Leukemia arm) and Cohort 2 (New Diagnosis arm) that are discovered by genomic analyses.
Rate of Results Reporting	2 Years	This Secondary Outcome will be addressed by a description of the time of results reporting. Documentation of the time of sample receipt and processing, resources and personnel utilized at each step of the process, time to results reporting, interpretation and review by Expert panel and communication of results to the primary oncologist will be captured.
Parent's Feelings and Understanding of Genomic Testing	2 Years	This Secondary Outcome will be addressed by describing the hopes and concerns of parents of children with recurrent/refractory/high-risk de novo leukemia regarding genomic testing of their child's leukemia as well as their understanding of the testing and evaluate whether the hopes and concerns were realized following the return of results.
Analysis of Primary Leukemia Sensitivity Testing and Establishment of Xenograft Models	2 Years	This Secondary Outcome will be addressed by completing analysis of the primary leukemia sensitivity testing to a panel of drugs or shRNA and establishing xenograft models in dedicated participating research laboratories and conducting co-clinical trials with the recommended matched therapy once the animal model is established.

Trial Locations

Locations (15)

UCSF Helen Diller Family Comprehensive Cancer Center; 🇺🇸 San Francisco, California, United States

Children's Hospital Colorado; 🇺🇸 Aurora, Colorado, United States

Johns Hopkins Hospital; 🇺🇸 Baltimore, Maryland, United States

Children's Hospital's and Clinics of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States

The Children's Hospital at Montefiore; 🇺🇸 Bronx, New York, United States

Washington University at St. Louis School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

Roswell Park Comprehensive Cancer Center; 🇺🇸 Buffalo, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States

Columbia University Medical Center; 🇺🇸 New York, New York, United States

Seattle Children's Hospital; 🇺🇸 Seattle, Washington, United States

Children's Healthcare of Atlanta; 🇺🇸 Atlanta, Georgia, United States

Children's Hospital of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

Dana Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

The University of Chicago; 🇺🇸 Chicago, Illinois, United States